A newly introduced bipartisan bill would permanently establish the Department of Veterans Affairs’ Precision Oncology Program for Cancer of the Prostate, known as POPCaP. The bill, H.R. 8553 or the POPCaP Authorization Act, was introduced by Rep. Greg Murphy, M.D., of North Carolina, with Rep. Herb Conaway, M.D., of New Jersey as a co-sponsor. The legislation is now under consideration by the House Veterans’ Affairs Committee.
The proposal focuses on preserving a VA program designed specifically for veterans with prostate cancer, rather than folding it into a broader oncology structure. Supporters argue that veterans face unique cancer risks because of service-related exposures, and that prostate cancer care should remain a dedicated area of VA research and treatment.
For veterans, the bill could have implications beyond treatment access. Prostate cancer is also a major VA disability issue, especially for veterans exposed to Agent Orange, burn pits, and other toxic substances during service.
What Is POPCaP?
POPCaP began after VA Research partnered with the Prostate Cancer Foundation in 2016 to improve prostate cancer care through precision oncology. The program uses genetic information to help tailor treatment for veterans with advanced prostate cancer. It also connects eligible patients with genetic testing, counseling, clinical trials, and FDA-approved drugs targeted to specific cancer mutations.
VA lists prostate cancer as the most commonly diagnosed cancer among U.S. veterans, accounting for 30 percent of new cancer diagnoses in VA. The program operates through a network of Precision Oncology Centers of Excellence and related VA facilities across the country.
Precision oncology matters because prostate cancer does not affect every patient the same way. Some veterans may have slower-growing disease, while others face aggressive or metastatic cancer. By looking at tumor genetics and other clinical data, doctors may be able to better match veterans with therapies or clinical trials that fit their specific cancer profile
Why Lawmakers Say the Bill Is Needed
Rep. Murphy’s office said VA planned to integrate POPCaP into a newly created broader Precision Oncology Program. The concern raised by the bill’s supporters is that merging POPCaP into a larger oncology structure could reduce the focus on prostate cancer and make it harder for veterans to access specialized treatment options.
ZERO Prostate Cancer, a national nonprofit focused on prostate cancer advocacy and patient support, has also backed efforts to protect the program. A 2025 ZERO Prostate Cancer document stated that Congress allocated $5 million in fiscal year 2024 to expand POPCaP to new sites, but that VA later outlined plans to shutter POPCaP sites, close its Seattle administrative office, and fold the program into a broader precision oncology program by September 2025.
The bill would direct VA to keep a prostate-cancer-specific precision oncology program in place. For veterans already receiving care through VA, the key issue is whether specialized prostate cancer research and treatment access remains clearly preserved within the VA health system.
Prostate Cancer and Toxic Exposure Claims
For many veterans, prostate cancer is not only a health diagnosis. It may also be connected to VA disability compensation.
VA recognizes prostate cancer as a presumptive condition for veterans exposed to Agent Orange or other herbicides during military service. That means eligible veterans with qualifying service and a prostate cancer diagnosis generally do not have to prove a direct medical link between their cancer and service to qualify for VA disability compensation and health care.
The PACT Act also expanded presumptive benefits for Gulf War era and post-9/11 veterans exposed to burn pits and other toxins. VA lists reproductive cancer of any type and genitourinary cancer among presumptive cancers connected to qualifying toxic exposure.
This is especially important for veterans whose prostate cancer was diagnosed years after service. A presumptive condition can reduce the burden of proof, but veterans still need evidence of diagnosis, qualifying service, and current residual symptoms if they are seeking an accurate VA rating.
How VA Rates Prostate Cancer
Under 38 CFR § 4.115b, Diagnostic Code 7528, malignant neoplasms of the genitourinary system are rated at 100 percent. After surgery, radiation, chemotherapy, or another therapeutic procedure ends, the 100 percent rating continues until a mandatory VA examination after six months. If there is no local recurrence or metastasis, VA then rates the condition based on residuals, usually voiding dysfunction or renal dysfunction, whichever is predominant.
That means a veteran’s rating may change after active treatment ends. Residual symptoms can include urinary frequency, leakage, obstructed voiding, kidney problems, or other complications. Under 38 CFR § 4.115a, voiding dysfunction can be rated as high as 60 percent when absorbent materials must be changed more than four times per day. Urinary frequency can be rated up to 40 percent when daytime voiding intervals are less than one hour or a veteran awakens to void five or more times per night.
Veterans should document symptoms carefully after treatment. Medical records, cancer treatment summaries, PSA history, prescriptions, pad usage, and statements about daily limitations can all affect how VA evaluates residuals.
What Veterans Should Watch Next
The POPCaP Authorization Act is still proposed legislation, not enacted law. Its progress through the House Veterans’ Affairs Committee will determine whether the bill advances further.
Veterans receiving prostate cancer care through VA should continue working with their oncology and urology teams and ask whether genetic testing, counseling, or clinical trials may be appropriate for their case. Veterans outside VA care may also want to ask whether they are eligible for VA health care, especially if they served in a toxic exposure location or already have a service-connected condition.
For veterans pursuing disability compensation, the most important step is making sure VA has the right evidence. A prostate cancer claim may involve active cancer, post-treatment residuals, toxic exposure history, secondary conditions, or survivor benefits for eligible family members.
Veterans Guide Can Help
A prostate cancer diagnosis can affect your health, your finances, and your family’s future. Veterans Guide helps veterans better understand VA benefits, disability ratings, appeals, and the evidence needed to move a claim forward.
If you are dealing with prostate cancer, toxic exposure, or VA disability questions, reach out to Veterans Guide for support and guidance. You do not have to navigate the VA system alone.
